LBA1 **Plenary Session**

Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

Jens Hoeppner, Thomas Brunner, Florian Lordick, Claudia Schmoor, Birte Kulemann, Ulf Peter Neumann, Gunnar Folprecht, Tobias Keck, Frank Benedix, Maximilan Schmeding, Ernst Reitsamer, Christiane J. Bruns, Johan F Lock, Benedikt Reichert, Michael Ghadimi, Kai Wille, Ines Gockel, Jakob R Izbicki, Stefan Utzolino, Peter Philipp Grimminger; University of Bielefeld, Bielefeld, Germany; Medical University of Graz, Department of Radiation Oncology, Graz, Austria; University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Department of Medicine, Leipzig, Germany; Clinical Trials Unit Freiburg, Medical Center, University of Freiburg, Freiburg, Germany; Department of Surgery, University Medical Center Schleswig-Holstein, Luebeck, Luebeck, Germany; Department of Hematology and Oncology, University Hospital Aachen, Aachen, Germany; University Hospital Carl Gustav Carus and Technische Universitat Dresden, Dresden, Germany; Department of Surgery, University Medical Center Schleswig-Holstein, Luebeck, Germany; Department of Surgery, University Hospital Magdeburg, Magdeburg, Germany; Department of Surgery, Klinikum Dortmund, Dortmund, Germany; Sana Klinikum Offenbach, Department of Hematology and Oncology, Offenbach Am Main, Germany; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Cologne, Germany; Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital, University of Wuerzburg, Wuerzburg, Germany; Department of General, Visceral, Thoracic, Transplantation, and Pediatric Surgery, UKSH Campus Kiel, Kiel, Germany; Department of General and Visceral Surgery, University Medical Center Goettingen, Goettingen, Germany; Department of Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, Ruhr-University Bochum, Minden, Germany; Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany; Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany; University Medical Center Mainz, Mainz, Germany

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2024, issue of the *Journal of Clinical Oncology*.

LBA2 **Plenary Session**

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta I. Lopez-Yurda, Alexander Christopher Jonathan van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne N Lo, Geke Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long; Netherlands Cancer Institute (NKI-AVL), Amsterdam, Netherlands; The Netherlands Cancer Institute, Amsterdam, Netherlands; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Melanoma Institute Australia, Wollstonecraft, NSW, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital, The Mater Hospital Sydney, Sydney, NSW, Australia; University Medical Center Groningen, Groningen, Netherlands; Melanoma Institute Australia and Westmead Hospital, Sydney, Australia; Isala Oncology Center, Zwolle, Netherlands; Leiden University Medical Center, Leiden, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands; Maria Skłodowska-Curie National Institute of Oncology Center, Warsaw, Poland; Peter MacCallum Cancer Center and the University of Melbourne, Melbourne, Australia; Erasmus MC, Rotterdam, Netherlands

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2024, issue of the *Journal of Clinical Oncology*.

LBA3 **Plenary Session**

Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.

Joseph A. Greer, Chardria Trotter, Vicki Jackson, Simone Rinaldi, Mihir Kamdar, Areej El-Jawahri, Nora K. Horick, Kedie Pintro, Dustin Rabideau, Josephine Louella Feliciano, Isaac S. Chua, Konstantinos Leventakos, Stacy Fischer, Toby Christopher Campbell, Michael W. Rabow, Finly Zachariah, Laura C. Hanson, Sara F. Martin, Maria Silveira, Jennifer S. Temel; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA; Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic College of Medicine, Rochester, MN; University of Colorado Anschutz Medical Campus, Aurora, CO; University of Wisconsin, Madison, WI; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; City of Hope National Medical Center, Madras, OR; School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Vanderbilt University Medical Center, Nashville, TN; University of Michigan Health, Ann Arbor, MI

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2024, issue of the *Journal of Clinical Oncology*.

LBA4 **Plenary Session**

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Suresh S. Ramalingam, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduardo Cronemberger, Xiangning Huang, Toon van der Gronde, Dana C. Ghiorghiu, Shun Lu; Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Oncology, Hanoi Medical University, Hanoi, Viet Nam; Mahidol University, Sriraj Hospital, Bangkok, Thailand; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan; Division of Pulmonary Oncology and Interventional Bronchoscopy, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Medical College of Chang Gung University, Taoyuan, Taiwan; Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain; Department of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey; Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina; Vietnam National Lung Hospital, Hanoi, Viet Nam; Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Centro de Pesquisa Clínica CRIO, Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil; Biometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Late-stage Development, Oncology R&D, AstraZeneca, New York, NY; Late-stage Development, Oncology R&D, AstraZeneca, Baar, Switzerland; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2024, issue of the *Journal of Clinical Oncology*.

LBA5 **Plenary Session**

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

David R. Spigel, Ying Cheng, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe Caro, Eva Lotte Buchmeier, John W. C. Chang, Isamu Okamoto, Sema Sezgin Goksu, Andrzej Badzio, Bethany Gill, Hema Gowda, Haiyi Jiang, Suresh Senan; Sarah Cannon Research Institute, Nashville, TN; Jilin Cancer Hospital, Changchun, China; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Federal State Budgetary Institution "N. N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation; Beijing Cancer Hospital, Beijing, China; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; National Cancer Center Hospital East, Kashiwa, Japan; Chungbuk National University Hospital, Cheongju, South Korea; Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China; Hospital Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Seville, Spain; Hospitals of the City of Cologne gGmbH, Cologne, Germany; Chang Gung Medical Foundation-LinKou Branch, Taoyuan City, Taiwan; Kyushu University Hospital, Fukuoka, Japan; Akdeniz University, Antalya, Turkey; Medical University of Gdansk, Gdansk, Poland; AstraZeneca, Mississauga, ON, Canada; AstraZeneca, Gaithersburg, MD; Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2024, issue of the *Journal of Clinical Oncology*.